Arcutis Biotherapeutics vs Tarsus Pharmaceuticals
ARQT and TARS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and TARS compare
Arcutis Biotherapeutics and Tarsus Pharmaceuticals are about the same size, with market caps of $3.4B and $3.5B.
Tarsus Pharmaceuticals grew revenue faster over the last twelve months (105% versus 76.1% for Arcutis Biotherapeutics).
Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 6.1% compared with −7.7% at Tarsus Pharmaceuticals.
Arcutis Biotherapeutics scores higher on the StockData Score (11 against 10 for Tarsus Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | TARS |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $3.5B |
| Share price | $27.15 | $78.68 |
| Change, 1 year | 18.8% | 8.5% |
| Change, 5 years | 62.9% | 215% |
| Beta (5Y) | 1.17 | 0.84 |
| Employees | 354 | 370 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 123× | – |
| P/S | 7.4× | 5.7× (better) |
| P/B | 15.5× | 10.0× (better) |
| EV/EBITDA | 95.8× | – |
| P/FCF | 87.2× | 61.7× (better) |
| FCF yield | 1.1% | 1.6% (better) |
| Fair value | $5.46 | $75.97 |
| Margin of safety | −397% | −3.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 76.1% | 105% (better) |
| Profitability | ||
| Gross margin | 91.1% | – |
| Operating margin | 7.4% (better) | −8.0% |
| Net margin | 6.1% (better) | −7.7% |
| FCF margin | 8.4% | 9.2% (better) |
| Return on equity | 15.9% (better) | −13.7% |
| Return on invested capital | 36.9% | – |
| Financial health | ||
| Debt / equity | 0.49 | 0.21 (better) |
| Net debt / EBITDA | −3.79 | – |
| Interest coverage | 2.5× (better) | −5.5× |
| Current ratio | 2.92 | 3.20 (better) |
| Altman Z-score | 6.33 | 8.29 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 110% |
| Held by insiders | 9.3% | 3.1% |
| Insider net buying, 12 months | −$11.1M (better) | −$20.0M |
| Short interest, % of float | 15.9% | 14.3% |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- TARS stock overview
- TARS income statement
- TARS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.